TY  - BOOK
AU  - Supuran,Claudiu T.
AU  - Simone,Giuseppina De
TI  - Carbonic anhydrases as biocatalysts: from theory to medical and industrial applications 
SN  - 9780444632630
AV  - QP613.C37 
U1  - 572.79 
PY  - 2015///]
CY  - Amsterdam
PB  - Elsevier
KW  - Carbonic anhydrase
KW  - Therapeutic use
KW  - Enzymes
KW  - Biotechnology
KW  - SCIENCE / Life Sciences / Biochemistry
KW  - bisacsh
KW  - Electronic books
N1  - Includes bibliographical references and index; Cover; Title Page; Copyright Page; Table of contents; List of Contributors; Preface; Part 1 -- Introduction; Chapter 1 -- Carbonic Anhydrases: An Overview; 1.1 -- Carbonic anhydrase families; 1.2 -- Catalytic features; 1.3 -- CA inhibition and activation; 1.4 -- Biomedical applications of the CAs; 1.5 -- Biotechnological applications of the CAs; References; Part 2 -- Carbonic Anhydrasesas Drug Targets; Chapter 2 -- Human Carbonic Anhydrases: Catalytic Properties, Structural Features, and Tissue Distribution; 2.1 -- Introduction; 2.2 -- hCAs' structural features; 2.3 -- hCAs' catalytic features; 2.4 -- hCAs' tissue distribution and their role as drug targetsReferences; Chapter 3 -- Carbonic Anhydrase I; 3.1 -- Introduction; 3.2 -- Structure of CA I; 3.3 -- Tissue localization and physiological functions; 3.4 -- CA I as pharmacological target; 3.5 -- CA I inhibitors; 3.6 -- CA I activators; 3.7 -- Conclusions and perspectives; Acknowledgment; References; Chapter 4 -- Carbonic Anhydrase II as Target for Drug Design; 4.1 -- Introduction; 4.2 -- Biochemical properties, genetic relationship with the other cytosolic isoforms, and 3D structure of hCA II; 4.3 -- hCA II inhibitors; 4.4 -- Antiglaucoma agents4.4.1 -- First-generation inhibitors; 4.4.2 -- Second-generation inhibitors: topically acting sulfonamides; 4.4.3 -- Third-generation inhibitors; 4.4.4 -- Dithiocarbamates and xanthates as topically acting antiglaucoma CAIs targeting hCA II; 4.5 -- Diuretics with CA inhibitory properties; 4.6 -- Agents for the management of altitude sickness; 4.7 -- Various pharmacological actions connected with CA II inhibition: serendipity or off-targeting with impressive efficacy?; 4.8 -- CA II inhibitors in the management of tumors?; 4.9 -- New strategies to design CA II-selective inhibitors4.10 -- CA II activation; 4.11 -- Conclusions; References; Chapter 5 -- Carbonic Anhydrase III; 5.1 -- Introduction; 5.2 -- Discovery of CA III; 5.3 -- Physiological role of CA III; 5.4 -- Molecular characterization of CA III; 5.5 -- Catalytic properties and proton transfer of CA III; 5.6 -- CA III as a biomarker: role in disease states; 5.7 -- CA III as a drug target; Acknowledgment; References; Chapter 6 -- Carbonic Anhydrase IV; 6.1 -- Introduction; 6.2 -- Genomic organization and chromosomal localization of human CA IV; 6.3 -- Cloning and molecular characterization of human CA IV6.4 -- Structure/function: the role of disulfide bonds; 6.5 -- Characterization of catalytic properties of human CA IV and its inhibition by sulfonamide inhibitors; 6.6 -- Expression of CA IV in different tissues; 6.7 -- Physiological functions of CA IV; 6.7.1 -- Kidney function; 6.7.2 -- Neuronal function; 6.7.3 -- Eye function; 6.7.4 -- Skeletal and cardiac muscle function; 6.7.5 -- CA IV functions in metabolons; 6.7.6 -- The role of CA IV in the taste of carbonation; 6.7.7 -- Disease-causing mutations in CA IV; 6.7.8 -- Kidney disease; 6.7.9 -- Environmental factors contributing to RP-17 associated with CA IV mutations
N2  - Carbonic anhydrases (CAs, EC 4.2.1.1) are ubiquitous metalloenzymes, present throughout most living organisms and encoded by five evolutionarily unrelated gene families. The Carbonic Anhydrases as Biocatalysts: From Theory to Medical and Industrial Applications presents information on the growing interest in the study of this enzyme family and their applications to both medicine and biotechnology
UR  - https://eresourcesptsl.ukm.remotexs.co/user/login?url=http://www.sciencedirect.com/science/book/9780444632586
ER  -